BACKGROUND:As a bone reconstruction material, nano-hydroxyapatite has good biocompatibility and osteoconduction, but the clinical use of nano-hydroxyapatite alone stil has many deficiencies. OBJECTIVE:To explore the in vivo osteogenic capability of nano-hydroxyapatite/ polyamide composites. METHODS: Twenty-four New Zealand white rabbits were subjected to humeral head replacement using nano-hydroxyapatite/polyamide composite material. X-ray observation and histological observation were done at 3, 6, 12, 24 weeks after replacement. RESULTS AND CONCLUSION: (1) X-ray observation: No thinned cortical bone and ectopic ossification occurred on the upper end of the composite material at different time, and the nano-hydroxyapatite/polyamide material had no signs of fragmentation. The cortical bone around the composite material was fuzzy, and the bone mineral density was increased with time. (2) Histological observation: At 3 weeks after replacement, a large number of cels could be visible, including mesenchymal stem cels and mononuclear macrophages. At 6 weeks after replacement, a large amount of fibrous tissues, fibroblasts and mononuclear macrophages stil existed in the boundary membrane, but chondrocytes and osteoblasts distributed less. At 12 weeks after replacement, a wide range of original trabecular bone began to form and were mostly flat that arranged regularly. At 24 weeks after replacement, the boundary membrane was ful of bone cels, but the cels on the surface of trabecular bone were relatively regular and primitive cels in the bone tissue began to transform into the lamelar bone. These findings indicate that the nano-hydroxyapatite/polyamide material has good osteogenic capability.

Objective Based on the teeth in vitro skull specimen to investigate the feasibility and accuracy of CARE kV CT scan for reducing radiation dose. Methods Of eight fixed and preserved skull teeth were scanned repeatedly in groups of A, B, C. In expose factors of 100 kVp/150 mAs in conventional scanning of group A, open CARE Dose 4D scan of group B and CARE kV scan of group C. We assessed the radiation dose in the group A, B and C, the average CT values of the images, noise, SNR, CNR and subjective ratings. Results Three groups of actual scan tube current, tube voltage and radiation dose were statistically significant (P < 0.05). Compared with group A, the radiation dose in the group B was reduced by about 13.76% and 26.61%reduced in the C group. The average CT values of the images and the noise SNR, CNR and subjective ratings hasd no significant difference (P > 0.05). Conclusion CARE kV technology based on the use specimens tooth can reduce the radiation dose, protect image quality, and be consistent to the reports of previous researches.

Objective To investigate the value of low kilovoltage (100 kVp)in combination with sinogram affirmed iterative re-construction (SAFIRE)of flash dual source CT in pelvic scan in comparison with routine kilovoltage (120 kVp)and filtered back projection (FBP).Methods 88 patients with suspected pelvic lesions underwent CT scan,and the range of BMI was 1 9 kg/m2

OBJECTIVETo investigate whether patients, who are at risk of major acute coronary events, are safe to undergo and benefit from early intervention after using simvastatin.

METHODSThe study was a randomized, open, two-dosage-controlled trial to evaluate the safety and benefits of simvastatin administered to 197 patients (10 mg group, n = 98 and 20 mg group, n = 99), within 48 hours of hospitalization for a diagnosis of unstable angina or acute myocardial infarction (MI), with total cholesterol (TC) >/= 180 mg/dL or low-density lipoprotein cholesterol (LDL-C) >/= 100 mg/dL. Lipid levels were measured immediately, followed by the 3rd, 6th and 12th month after admission and all adverse events were recorded during follow-up.

RESULTSTC levels fell by 10.15% and 14.52% in the 10 mg and 20 mg groups (P < 0.05), and LDL-C levels fell 13.87% and 19.38% in the 10 mg and 20 mg groups, respectively (P < 0.01), 12 months after using simvastatin. The rates of achieving target TC reached 26.3% and 36.5% in the 10 mg and 20 mg groups (P < 0.01), and that of LDL-C reached 28.2% and 40.3% in the 10 mg and 20 mg groups, respectively (P < 0.01). There were higher rates of MI and re-hospitalization resulting from angina pectoris and revascularization in the 10 mg group compared with the 20 mg group.

CONCLUSIONSThe results suggest that early intervention with the HMG-CoA reductase inhibitor, simvastatin, in acute coronary syndromes is possible and safe. It also indicates that the clinical dosage of simvastatin are relatively smaller than that for satisfactory lipid control in patients with acute coronary syndromes.

Acute Disease ; Aged ; Cholesterol ; blood ; Cholesterol, LDL ; blood ; Coronary Disease ; blood ; drug therapy ; Female ; Follow-Up Studies ; Humans ; Hypolipidemic Agents ; therapeutic use ; Male ; Middle Aged ; Simvastatin ; therapeutic use